BDBM652591 2-methyl-N-((4-methyl-6-(3-(trifluoromethyl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin- 7(8H)-yl)pyridin-3-yl)methyl)-1H-pyrrolo[2,3-c]pyridin-4-amine::US20240059691, Example 1341

SMILES Cc1cc2c(NCc3cnc(N4CCn5c(nnc5C(F)(F)F)C4)cc3C)cncc2[nH]1

InChI Key InChIKey=BSYGQRQUDPTXKF-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 652591   

TargetCoagulation factor XII(Human)
Kalvista Pharmaceuticals

US Patent
LigandChemical structure of BindingDB Monomer ID 652591BDBM652591(US20240059691, Example 1341 | 2-methyl-N-((4-methy...)
Affinity DataIC50: 2.00E+3nMAssay Description:In vitro inhibition of Factor XIIa was determined using an IC50 assay based on standard literature methods (see e.g Baeriswyl et al., ACS Chem. Biol....More data for this Ligand-Target Pair
In Depth
Date in BDB:
4/24/2024
Entry Details
US Patent